Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...

The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and Exchange ...

potentially reducing side effects compared to traditional myostatin inhibitors. Financially, Scholar Rock is well-positioned with a market cap of $4.19bn and a cash runway extending past initial ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

IBIO-600 showed potent myostatin inhibition in preclinical studies, with clinical trials in obesity planned for 2026. Get Real-Time News and Alerts for Your Portfolio In March, iBio collaborated ...

Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...

Research indicates that IGF-1 LR3 may stimulate cellular proliferation and development, improve lipid metabolism, and promote muscle regeneration and hypertrophy by inhibiting myostatin.

our highly selective myostatin inhibitor specifically designed for obesity and cardiometabolic disorders.” 2025 Strategic Priorities and Upcoming Milestones: Scholar Rock plans to focus on three ...